Association of genetic variations and weight loss response to naltrexone/bupropion
Weight Loss Study: Genetic Variations and Response to Naltrexone/Bupropion
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases
Enrolling: Male and Female Patients
Study Length: 40 Weeks
Clinic Visits: 6
IRB Number: AAAU3131
U.S. Govt. ID: NCT05919797
Contact: Sarah Borden: 212-305-4006 / weightlossstudy@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate if genetic variations are associated with the amount of weight loss with diet and while taking an FDA-approved medication for weight loss. The participation lasts ten months and includes six in-person visits at CUIMC with blood sampling and questionnaires, virtual nutritional counseling, and taking an oral weight loss medication for 28 weeks.
Investigator
Judith Korner, MD
Do You Qualify?
Are you between the ages of 18 and 65? Yes No
Do you have diabetes? Yes No
Do you have a history of previous bariatric surgery? Yes No
Do you have obesity or are you overweight? Yes No
Do you live in the New York City tristate area (NY, NJ, CT)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Sarah Borden
weightlossstudy@cumc.columbia.edu
212-305-4006
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE